Dunamu & Partners Makes Follow-Up Investment in Medical AI Firm AIRS Medical, Cumulative Total Reaches 9.7 Billion Won
Follow-up Investment After Initial 2024 Funding
"Adopted by Over 1,700 Medical Institutions in 40 Countries Worldwide"
Dunamu & Partners announced on July 2, 2026, that it has made a follow-up investment in AIRS Medical, an artificial intelligence (AI)-based medical imaging solution company. This investment is seen as a response to the growing trend among medical institutions to focus on optimizing existing infrastructure rather than introducing new equipment.
A representative from Dunamu & Partners stated, "Since first participating in AIRS Medical's Series C round in 2024, we have invested a cumulative total of 9.7 billion won through this round." The representative further noted that global private equity fund TA Associates, which manages assets totaling USD 65 billion (approximately 101 trillion won), also participated in this funding round. The specific investment amount, however, was not disclosed.
AIRS Medical, founded in Korea, is a leading medical AI company that has distinguished itself in overseas markets. The company provides AI solutions such as 'SwiftMR,' which reduces MRI scan times by up to 50% while restoring low-quality images to high-quality, and 'SwiftSite,' a platform for MRI quantification and structured reporting.
With these solutions, medical institutions can improve the utilization of existing equipment and increase examination throughput, while patients benefit from shorter exam durations. Currently, more than 1,700 medical institutions in over 40 countries worldwide have adopted AIRS Medical's solutions, applying the technology to over 6 million examinations annually.
AIRS Medical plans to use this investment to strengthen its global market presence and enhance its product competitiveness. The company will also accelerate the advancement of its AI-based MRI solutions and the development of new products.
Lee Hyesung, Chairman of the Board at AIRS Medical, stated, "Dunamu & Partners' continued participation from Series C through the current round is a testament to their consistent trust in AIRS Medical's global expansion strategy. With TA Associates joining as a new partner, we will work together to ensure that a medical AI company born in Korea can become a category leader in the global market."
Park Jangsoon, CEO of AIRS Medical, commented, "This round reflects the market's recognition of AIRS Medical's achievements in the global market. During negotiations and closing, the experience and strategic insight that Dunamu & Partners has accumulated through managing overseas investment portfolios were invaluable."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
CEO Park emphasized, "AIRS Medical is a leading example of Korean deep tech, demonstrating its potential by starting in Korea, gaining recognition for technological competitiveness in the global market, and attracting investment from global investors. We will actively support the company's growth as a long-term partner to ensure it can advance to the next level on the global stage."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.